Converging evidence in support of omega-3 polyunsaturated fatty acids as a potential therapy for Huntington’s disease symptoms
Author:
Vega Owen M.1, Cepeda Carlos1
Affiliation:
1. Intellectual and Developmental Disabilities Research Center, Jane and Terry Semel Institute for Neuroscience & Human Behavior, David Geffen School of Medicine, University of California Los Angeles , 760 Westwood Plaza , Los Angeles , CA 90095 , USA
Abstract
Abstract
Huntington’s disease (HD) is a genetic, inexorably fatal neurodegenerative disease. Patient average survivability is up to 20 years after the onset of symptoms. Those who suffer from the disease manifest motor, cognitive, and psychiatric impairments. There is indirect evidence suggesting that omega-3 polyunsaturated fatty acids (ω-3 PUFA) could have alleviating effects on most of HD symptoms. These include beneficial effects against cachexia and weight loss, decrease of cognitive impairment over time, and improvement of psychiatric symptoms such as depression and irritability. Furthermore, there is a positive correlation between consumption of ω-3 PUFAs in diets and prevalence of HD, as well as direct effects on the disease via release of serotonin. Unfortunately, to date, very few studies have examined the effects of ω-3 PUFAs in HD, both on the symptoms and on disease progression. This paper reviews evidence in the literature suggesting that ω-3 PUFAs can be used in neurodegenerative disorders. This information can be extrapolated to support further research of ω-3 PUFAs and their potential use for HD treatment.
Publisher
Walter de Gruyter GmbH
Subject
General Neuroscience
Reference117 articles.
1. Arterburn, L.M., Hall, E.B., and Oken, H. (2006). Distribution, interconversion, and dose response of ω-3 fatty acids in humans. Am. J. Clin. Nutr. 83: 1467S–1476S. 2. Aryal, S., Hussain, S., Drevon, C.A., Nagelhus, E., Hvalby, Ø., Jensen, V., Walaas, S.I., and Davanger, S. (2019). Omega-3 fatty acids regulate plasticity in distinct hippocampal glutamatergic synapses. Eur. J. Neurosci. 49: 40–50. 3. Avallone, R., Vitale, G., and Bertolotti, M. (2019). Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. Int. J. Mol. Sci. 20: 4256. 4. Aziz, N.A., Van Der Burg, J.M.M., Landwehrmeyer, G.B., Brundin, P., Stijnen, T., and Roos, R.A.C. (2008a). Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71: 1506–1513. 5. Aziz, N.A., Van Der Marck, M.A., Pijl, H., Olde Rikkert, M.G.M., Bloem, B.R., and Roos, R.A.C. (2008b). Weight loss in neurodegenerative disorders. J. Neurol. 255: 1872–1880.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|